Our vision is to increase the efficacy of translation of its world class fundamental research, and its impact upon clinical practice and patient wellbeing.
Professor Mark Wills
Our vision is to increase the efficacy of translation of its world class fundamental research, and its impact upon clinical practice and patient wellbeing.
Professor Mark Wills
Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing
18 March 2025
Maxion Therapeutics, a Cambridge-based biotechnology company co-founded by Dr. John McCafferty, Associate Professor at CITIID and the Department of Medicine, University of Cambridge, has successfully raised $72 million in an oversubscribed Series A financing round. The company is developing antibody-based KnotBody® drugs...
When inflammation goes too far
13 March 2025
Clare Bryant takes a closer look at inflammation, and when our defence systems go too far.
Microbiome: ‘Good’ gut bacteria may protect against Salmonella infection
4 March 2025
New research from scientists at the University of Cambridge reveals how ‘good’ gut bacteria help protect against Salmonella, a major cause of food poisoning.
© 2025 University of Cambridge
